Iipayipi

I-R&D ye-Sorrento igxile ekuqhubeni izinto ezintsha kwi-COVID-19, unyango lomhlaza, ulawulo olupheleleyo lweentlungu kunye nezifo ezizimelayo.

IiNkqubo eziPhambili Ukubonisa Ulungelelaniso Isigaba I Isigaba II Isigaba III/engundoqo Ukuvunyelwa kwe-FDA
Iinkqubo ze-COVID-19  

COVISTIX™ (uxilongo) Uvavanyo lweAntigen olukhawulezayo

*

Ugunyaziso lokuSebenzisa oluNgxamisekileyo (EUA) eMexico (COFEPRIS), eBrazil (ANVISA), kunye neCE Ephawulwe eYurophu

COVIMARK™ (uxilongo) Uvavanyo lweAntigen olukhawulezayo

*

Isicelo singeniswe e-US naseKhanada kuGunyaziso lokuSebenzisa oluNgxamisekileyo (EUA)

VIREX (uxilongo) Kwi-Diagnostic yasekhaya

60.2%*

EUA Enabling Studies in Q3 2022

OQORY™ (COVI-MSC) I-ARDS ngenxa ye-COVID-19 kwizigulana zase-ICU

82%*

Uvavanyo olubalulekileyo eBrazil

                         
OVYDSO (Olgotrelvir)Anti-intsholongwane (Ipilisi yomlomo)

40%*

Ugonyo lwe-Omicron mRNA Igciwane

20%*

IiNkqubo eziPhambili Ukubonisa Ulungelelaniso Isigaba I Isigaba II Isigaba III/engundoqo Ukuvunyelwa kwe-FDA
immunotherapy  

FUJOVEE™ (Abivertinib) I-NSCLC

82%*

FUJOVEE™ (Abivertinib) B IiLymphomas zeeseli

60.2%*

FUJOVEE™ (Abivertinib) Prostate

20%*

PD-L1 (Socazolimab)* I-SCLC

82%*

*Ngentsebenziswano neLee's Pharm eTshayina

I-PD-L1 (STI-3031)** Ngomhlaza wesibeleko

82%*

**E-US kunye nentsebenziswano ne-ImmuneOncia eKorea

CD47 Amathumba aqinileyo

40%*

I-CD38 DAR-T Multiel Myeloma

40%*

CD38 ADC I-Amyloidosis, i-Myeloma emininzi, i-T-ALL, kunye ne-esophageal

40%*

TROP2 ADC* Amathumba aqinileyo

40%*

Intsholongwane kaSeprehvec™ oncolytic Amathumba aqinileyo; CNS Amathumba

40%*

BCMA ADC Amathumba olwelo

20%*

Bevacizumab-ADAB™ Umhlaza weSifo seNtsholongwane

40%*

Ngentsebenziswano neMayo Clinic

Bevacizumab-ADAB™ I-Ovarian Cancer

40%*

Ngentsebenziswano neMayo Clinic

I-Rituximab-ADAB™ I-B-cell Lymphomas

40%*

Ngentsebenziswano neMayo Clinic

Sofusa® i-anti-PD-1 I-Cutaneous T-Cell Lymphoma (CTCL), iMelanoma

40%*

IiNkqubo eziPhambili Ukubonisa Ulungelelaniso Isigaba I Isigaba II Isigaba III/engundoqo Ukuvunyelwa kwe-FDA
Ubuhlungu  

ZTlido® 1.8%
I-Posterpetic Neuralgia - PHN

99.8%*

Gloperba®
Unyango lweGout (ngomlomo)

99.8%*

SEMEXA (SP-102) I-Lumbar Radicular / Sciatica Pain

82%*

I-SP-103 (I-Lidocaine Topical System 5.4%) Ubuhlungu be-Acute back

60.2%*

I-SP-104 (Idosi eLityazisiweyo yokuGqiswa kweNaltrexone) Fibromyalgia

20%*

I-RTX (i-resiniferatoxin)
Isitofu se-epidural
Intlungu engenakunyanzeliswa kwi-Cancer Advanced

60.3%*

Ukubizwa kwenkedama

I-RTX (i-resiniferatoxin)
Indlela ye-Intra-articular
Iintlungu ze-OA zedolo eliPhakathi ukuya kutsho kweMandundu

60.2%*

IiNkqubo eziPhambili Ukubonisa Ulungelelaniso Isigaba I Isigaba II Isigaba III/engundoqo Ukuvunyelwa kwe-FDA
Ukuhanjiswa kweziyobisi kwiLymphatic  

Sofusa® I-anti-TNF Amajoni omzimba (RA)

40%*

Sofusa® i-anti-PD-1 I-Cutaneous T-Cell Lymphoma (CTCL), iMelanoma

40%*

Sofusa® anti-CTLA-4 IMelanoma

40%*

Ngentsebenziswano neMayo Clinic
Iinkqubo ze-COVID-19
IiNkqubo eziPhambili (Isalathiso) Isigaba
COVISTIX™ (uxilongo) FDA EUA
COVIMARK™ (uxilongo) FDA EUA
VIREX (uxilongo) PH III
FUJOVEE™ (Abivertinib) Ph III
OQORY™ (COVI-MSC) Ph III
I-OVYDSO (Olgotrelvir) Ph II
Ugonyo lwe-Omicron mRNA Ulungelelaniso
immunotherapy
IiNkqubo eziPhambili (Isalathiso) Isigaba
FUJOVEE™ (Abivertinib) Ph III
FUJOVEE™ (Abivertinib) Ph II
FUJOVEE™ (Abivertinib) Ulungelelaniso
I-PD-L1 (Socazolimab)* Ph III
I-PD-L1 (STI-3031)** Ph III
CD47 (Iithumba eziqinileyo) Ph I
I-CD38 DAR-T (Multiple Myeloma) Ph I
CD38 ADC (I-Amyloidosis, i-Myeloma emininzi, i-T-ALL, kunye ne-esophageal) Ph I
TROP2 ADC* (Iithumba eziqinileyo) Ph I
Intsholongwane kaSeprehvec™ oncolytic (Iithumba eziqinileyo; CNS Tumors) PH I
BCMA ADC (Amathumba olwelo) Ulungelelaniso
Bevacizumab-ADAB™ (Umhlaza we-Endometrial) Ph I
Bevacizumab-ADAB™ (Umhlaza wesibeleko) Ph I
I-Rituximab-ADAB™ (B-cell Lymphomas) Ph I
Sofusa® i-anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL), iMelanoma) Ph I
Ubuhlungu
IiNkqubo eziPhambili (Isalathiso) Isigaba
ZTlido® 1.8% (I-Postherpetic Neuralgia - PHN) Ukuvunyelwa kwe-FDA
Gloperba® 1.8% Unyango lweGout (ngomlomo) Ukuvunyelwa kwe-FDA
SEMEXA (SP-102) Ph III
I-SP-103 (I-Lidocaine Topical System 5.4%) Ph II
I-SP-104 (Idosi eLityazisiweyo yokuGqiswa kweNaltrexone) Ulungelelaniso
I-RTX (i-resiniferatoxin) Isitofu se-epidural Ph II
I-RTX (i-resiniferatoxin) Indlela ye-Intra-articular Ph II
Ukuhanjiswa kweLymphatic
IiNkqubo eziPhambili (Isalathiso) Isigaba II
Sofusa® I-anti-TNF (Autoimmune RA) Ph I
Sofusa® i-anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL), iMelanoma) Ph I
Sofusa® anti-CTLA-4 (Imelanoma) Ph I